-
Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment
•
Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) approval for its drug candidate, HPG7233. This small-molecule thyroid hormone receptor beta (THR-β) agonist is poised for development as a treatment for non-alcoholic steatohepatitis (NASH) and…
-
Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study
•
China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase IIa clinical study of its in-house developed FXR agonist HPG1860 in non-alcoholic steatohepatitis (NASH). The results highlight the drug’s potential in addressing this metabolic liver disease. Phase IIa RISE Study ResultsThe multi-center, randomized, double-blind, placebo-controlled…
